A familial Wilms' tumour susceptibility gene, known as FWT1, has recently been localised to chromosome 17q12-q21 by genetic linkage analysis. Four Wilms' tumours from a family showing strong evidence of linkage to FWT1 were examined for allele loss using polymorphic microsatellite markers on chromosome 17q. In three tumours no loss of heterozygosity was observed. In the remaining case, loss of heterozygosity was detected at all markers analysed. However, the alleles lost in this Wilms' tumour were those segregating with the disease in the family. This is in contrast to the usual pattern observed in familial cancer syndromes, where the allele lost in tumours arising in gene carriers is the wild type inherited from the non mutation carrying parent. Taken together with previous data indicating that LOH on chromosome 17q is rare in sporadic Wilms' tumour, the results suggest that FWT1 is not a tumour suppressor gene. Moreover, loss of alleles linked to the disease and the implied absence of the mutated susceptibility gene in one tumour, suggests that a mutation in FWT1 may be necessary for the initiation of some familial Wilms' tumours but subsequently the maintenance of the neoplastic phenotype becomes independent of the FWT1 mutation.
Keywords: Wilms' tumour; loss of heterozygosity; dominant oncogene; tumour suppressor gene Wilms' Tumour (WT) is an embryonal tumour of the kidney that aects 1 in 10 000 children. Approximately 1% of WT cases cluster in families in which the disease appears to be inherited as an autosomal dominant trait (Breslow and Beckwith, 1982) . Although genes at chromosomes 11p13 (WT1), 11p15 and 16q have been implicated in the genesis of WT, none of these account for a substantial proportion of families in which there is clustering of WT cases (Grundy et al., 1988; Hu et al., 1988 Hu et al., , 1992 Schwartz et al., 1991) . We recently localised a familial WT predisposition gene, FWT1, to chromosome 17q12-q21 by genetic linkage analysis of a large Canadian pedigree (MON 480) (Rahman et al., 1996) . Subsequent analyses have identi®ed another family with six cases of WT that is highly likely to be due to FWT1, thus con®rming the location of the gene (Rahman et al., submitted) .
Most cancer susceptibility genes require mutation of both alleles in the cancer cell for oncogenesis to proceed and conform to the genetic model ®rst proposed for retinoblastoma. The ®rst mutation is inherited in the germline in familial cancers and in many genes may also occur as a somatic event in sporadic cancers. The second mutation in both cases occurs somatically and is often detectable as loss of heterozygosity (LOH) of polymorphic markers located in the vicinity of the gene (Knudson, 1993) . The mutations usually result in inactivation of critical functions served by the encoded proteins. In cancers arising in mutation carriers, loss of heterozygosity in the vicinity of the susceptibility gene is usually seen in a high proportion of tumours and the allele lost is almost always the wild type inherited from the non mutation carrying parent. This pattern of events has been reported in familial retinoblastoma due to the RB1 gene (Cavenee et al., 1985) , familial breast and other cancers due to the BRCA1 and BRCA2 genes (Collins et al., 1995; Smith et al., 1992) , familial renal and other neoplasms due to mutations in the VHL gene (Shuin et al., 1994) , familial neuro®brosarcomas and phaeochromocytomas due to the NF1 gene (Legius et al., 1993; Xu et al., 1992) , familial schwannomas and meningiomas due to the NF2 gene (Twist et al., 1994) , colorectal adenomas and carcinomas due to APC and MLH1 genes (Hemminki et al., 1994; Levy et al., 1994) , and familial cylindromas due to the cyld1 gene (Biggs et al., 1995) . To evaluate in a preliminary fashion the mechanism of action of FWT1 we have examined allele loss in WT from a family in which the disease is clearly linked to this gene.
Formalin ®xed, paran embedded specimens from six WT from MON 480 were obtained from histopathology archives. The WT were from individuals no. 11, no. 12, no. 22, no. 26, no. 52 and no. 59 in the pedigree illustrated in Rahman et al. (1996) . The diagnoses were reviewed and con®rmed as WT. In ®ve cases the tumour showed the triphasic pattern typical of WT and in one, (no. 12), the tumour was predominantly myogenic. DNA extracted from these samples was examined for allele loss in the vicinity of FWT1 using the markers, D17S927, D17S250, D17S800, D17S579 and D17S787. The order of markers in this interval is centromere ± D17S927 ± 2.5cM ± D17S250 ± 2cM ± D17S800 ± 2cM ± D17S579 ± 7.5cM ± D17S1820 ± 2cM ± D17S787 ± telomere. Critical recombinants in MON 480 indicate that FWT1 is located between D17S927 and D17S1820.
DNAs from two tumour samples (no. 26 and no. 22) repeatedly failed to amplify in the PCR, limiting the analysis to four tumours. DNA from the tumour of individual no. 52 only gave results in the ®rst three ampli®cations and thereafter failed. Of the 20 genotypings of normal tissues, only one was homozygous. The results obtained using D17S800 in the WT from no. 11, no. 12 and no. 59 and using D17S579 in the WT from no. 52 are illustrated in Figure 1 . In three tumours there is no evidence of allele loss. In the fourth, from individual no. 12, LOH was observed at all ®ve markers used. Surprisingly, the allele lost at each marker is the one linked to the disease in MON 480.
Chromosomes 11p13, 11p15 and 16q do not appear to harbour major familial WT susceptibility genes, but they are frequent sites of LOH in sporadic WT. Approximately 30% of sporadic WT exhibit LOH at chromosome 11p and in one third of these loss is restricted to 11p15 . Almost invariably it is the maternal allele that is lost, and this is believed to occur because the paternal alleles of critical genes in this region are imprinted and hence inactivated . Allele loss has also been demonstrated at chromosome 16q in 20% of sporadic WT (Maw et al., 1992) . We have evaluated the role of these putative tumour suppressor genes in WT arising in FWT1 mutation carriers, by examining for allele loss in these regions. Three tumours (no. 11, no. 12 and no. 59) were examined for LOH at chromosome 11p15 using marker D11S922, at chromosome 11p13 using markers D11S904 and D11S907 which¯ank WT1 and at chromosome 16q22 using D16S503 and D16S515. In two tumours (no. 12 and no. 59) allele loss at all three loci on chromosome 11p was observed (data not shown) and in the remaining tumour no allele loss was detected. In both familial WT showing LOH on chromosome 11p it was the maternal allele that was lost, corresponding to the pattern seen in sporadic WT.
This suggests that additional genetic events, similar to those seen in sporadic WT may be required for the development of WT in FWT1 mutation carriers. None of the three familial WT showed allele loss at chromosome 16q.
Previous analyses of sporadic WT have shown that LOH on chromosome 17q is rare (one out of 22 and 0 out of 13 in (Maw et al., 1992) and (Rahman et al., 1996) , respectively). The present study demonstrates that loss of the wild type allele does not occur in WT arising in FWT1 mutation carriers. It is possible that in sporadic and/or familial WT, FWT1 is being inactivated by small genetic events which are not detectable using markers a few centimorgans distant from the gene. However, this would not conform to the pattern observed in the cancer susceptibility syndromes listed above, in which LOH is usually observed at large genetic distances from the predisposition gene. An alternative explanation is that allele loss in WT cells is obscured by contamination with non neoplastic cells. However, the histology of the samples indicates that all contain more than 90% tumour cells which should allow unambiguous detection of allele loss. Moreover, LOH at 11p in two tumours demonstrates that allele loss is detectable in these samples.
Most cancer susceptibility genes are believed to be tumour suppressor genes/recessive oncogenes, but at least one does not conform to this genetic model. The RET proto-oncogene on chromosome 10q11.2 encodes a receptor tyrosine kinase expressed in neural crestderived tissues (Nakamura et al., 1994) . Mutations in RET have been demonstrated in the germline in multiple endocrine neoplasia (MEN) 2A, 2B and familial medullary thyroid cancer (FMTC) and occur somatically in a proportion of sporadic MTC (Carlson et al., 1994; Donis Keller et al., 1993; Eng et al., 1995; Hofstra et al., 1994; Mulligan et al., 1993b) . In contrast to mutations found in tumour suppressor genes, mutations in RET are restricted to a small number of amino acids and are not predicted to result in truncation of the encoded protein. Disease causing Figure 1 Phosphorimager traces of 32 P-labeled, PCR ampli®ed chromosome 17q microsatellite repeats in the vicinity of FWT1, in four individuals with WT from MON 480. Results using D17S800 in no. 11, no. 12 and no. 59 and D17S579 in no. 52 are shown. The solid arrows indicate the allele that is linked to the disease. The open arrows indicate the wild type allele from the non mutation carrying parent. The numbers beneath the traces identify the individuals within the family and correspond to those used in Rahman et al. (1996) . The allele linked to the disease is absent from the tumour of no. 12 mutations in the extracellular domain of RET in MEN2A and in the tyrosine kinase domain in MEN2B have been demonstrated to constitutively activate the RET kinase and convert RET to a dominant transforming gene. (Santoro et al., 1995; Xing et al., 1996) . Furthermore, allele loss in the vicinity of RET is extremely uncommon in MEN2 and familial and sporadic MTC, despite the frequent occurrence of LOH at other loci in the same tumours (Landsvater et al., 1989; Mulligan et al., 1993a; Nelkin et al., 1989) .
Although we have only examined four tumours from FWT1 carriers, in the majority of familial cancer syndromes attributable to tumour suppressor genes LOH in the vicinity of the susceptibility gene is seen in a high proportion of familial tumours, and would usually be demonstrable in a small number of samples. We therefore propose that absence of loss of the wild type allele in familial WT and absence of LOH on chromosome 17q in sporadic WT indicates that FWT1 is not a tumour suppressor gene. Instead, following the precedent of RET in MEN2 and MTC, we postulate that mutation of a single FWT1 allele in a tumour cell may be sucient to contribute to oncogenesis and that the FWT1 protein may be activated by the mutations that confer susceptibility to cancer.
Loss of marker alleles that are linked to WT in MON 480 was observed in one tumour. Since the markers D17S927 and D17S787¯ank FWT1 and are both informative in this case, it is likely that the mutated copy of FWT1 that is responsible for susceptibility to WT in this family is actually absent from this cancer. (A theoretically possible, but much less likely, alternative is that during normal development and/or oncogenesis a double somatic recombination has taken place between FWT1 and the two chromosome 17q markers that directly¯ank it). Loss of the mutated copy of the FWT1 gene from the tumour is consistent with neither the recessive nor the dominant model of oncogene action. The results suggest, however, that once the malignant process has been initiated, the mutant FWT1 gene is no longer required for maintenance of the neoplastic phenotype or for progression of the tumour. This type of`hit and run' oncogenesis is compatible with a mutated gene which confers genomic instability and hence acquisition of further abnormalities in other cancer associated genes, or a gene which expands substantially the population of target progenitor cells and hence increases the likelihood that at least one will become neoplastic. Studies of additional WT from FWT1 linked families and subsequently the isolation of FWT1 itself, may lead to the clari®cation of these hypotheses.
